feed,title,long_url,short_url
Benzinga,Advaxis' ADXS-503 Shows Durable Benefit Beyond One Year in Lung Cancer Patients Progressing on Merck's Keytruda,https://benzinga.com/general/biotech/21/05/21217332/advaxis-adxs-503-shows-durable-benefit-beyond-one-year-in-lung-cancer-patients-progressing-on-mer,https://j.mp/3ozFmHT
